IDH1 and cancer: Exploiting nicotinamide adenine dinucleotide (NAD+, a coenzyme involved in redox reactions during DNA repair) depletion pathways in IDH-mutant cancers presents a promising strategy to enhance the response to chemotherapy-induced DNA damage and improve the long-term effectiveness of therapy [31].